首页> 外文会议>International Congress on Electrocardiology >THE SUPPRESSIVE EFFECT OF BEPRIDIL ON ATRIALFLUTTER ORGANIZED FROM PERSISTENT ATRIALFIBRILLATION DURING CLASS IC ANTIARRHYTHMICTHERAPY
【24h】

THE SUPPRESSIVE EFFECT OF BEPRIDIL ON ATRIALFLUTTER ORGANIZED FROM PERSISTENT ATRIALFIBRILLATION DURING CLASS IC ANTIARRHYTHMICTHERAPY

机译:在IC抗真菌治疗过程中从持续的故障学习中组合的Bepridil对AtrialFlouter的抑制作用

获取原文

摘要

Background: Combination therapy of class Ic antiarrhythmic drugs (AAD) and bepridil have been reported safe and effective on conversion from atrial fibrillation (AF) to sinus rhythm (SR). The aim of this study was to examine the efficacy of bepridil for atrial flutter (AFL), which developed from persistent AF while taking class Ic AAD. Methods and Results: In 16 of 64 patients with persistent AF, conversion from AF to AFL was observed after administration of class Ic AAD. Moreover, 15 of 16 patients were restored to SR 35+-5 days after taking bepridil and 12 of 15 patients maintained SR during follow-up of 24+-5 months. The 16 patients were divided into the two groups, depending on whether AF was changed to typical (GroupA:n=10) or atypical AFL (GroupB:n=6). In GroupA, AFL converted to SR in all patients compared to 5 of 6 patients in GroupB, and AF recurred spontaneously in 0% of GroupA vs. 60% of GroupB (p<0.01) during follow-up period. There were no significant differences between the two groups in patient characteristics.Conclusion: In the patients with persistent AF converting typical AFL during class Ic AAD, combination therapy with additional administration of bepridil may be useful for maintenance of SR.
机译:背景:据报道,IC抗真菌药物(AAD)和Bepridil的组合治疗安全有效地从心房颤动(AF)转化为窦性心律(SR)。本研究的目的是检查百分子对心房扑动(AFL)的疗效,这在采取级别AAD时从持久性AF开发。方法和结果:在64例持久性AF患者中,在施用IC AAD的施用后观察到AF至AFL的转换。此外,在服用Bepridil后,16名患者中的15例恢复到SR 35 + 5天,在24 + 5个月的随访期间维持SR。将16名患者分为两组,取决于AF是否被改变为典型(Groupa:n = 10)或非典型AFL(Groupb:n = 6)。在Groupa中,AFL在所有患者中转化为SR,而在组织中的5名患者中的5名患者中,AF在随访期间在Grataa的0%中自发地重复,在随访期间,G组的0%(P <0.01)。两组之间的两组在患者特征之间没有显着差异。结论:在IC AAD期间典型AFL典型AFL的患者中,与额外的BEPRIDIL组合治疗可用于维持SR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号